Press "Enter" to skip to content

Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer – Associated Press

admin 0

Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer  Associated Press

Press release *content* from Business Wire. The AP news staff was not involved in its creation.

“cervical cancer” – Google News

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *